Design of clinically useful iron(III)-selective chelators

Medicinal Research Reviews

Volumn 22, Issue 1, 2002, Pages 26-64

  Liu, Zu D ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Hydroxypyridinone; Iron chelators; PFe3+ value; Prodrug

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; DEFEROXAMINE; HYDROXAMIC ACID; IRON CHELATING AGENT; PHENOL DERIVATIVE; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

CHELATION; DRUG DESIGN; DRUG USE; IRON METABOLISM; IRON OVERLOAD; LIGAND BINDING; REVIEW;

BIOLOGICAL AVAILABILITY; DRUG DESIGN; HUMANS; IRON CHELATING AGENTS;

EID: 0036136401     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.1027     Document Type: Review

References (161)

1. Medical progress: Disorders of iron metabolism
2. Tissue-specific regulation of iron metabolism and heme synthesis: Distinct control mechanisms in erythroid cells
3. The control of cellular iron homeostasis
4. Disorders of iron metabolism: Deficiency and overload
5. Iron chelators for thalasaemia
6. Facilitation of Fe(II) autoxidation by Fe(III) complexing agents
7. Siderophore mediated absorption of iron
8. 3+
9. Complexation of iron by siderophores: A review of their solution and structural chemistry and biological function
10. Rational reduction of the conformational space of a siderophore analog through nonbonded interactions: The role of entropy in enterobactin
11. Conformationally rigid tricyclic tripods: Synthesis and application to preparation of enterobactin analogs
12. Ferric ion sequestering agents 15. Synthesis, solution chemistry, and electrochemistry of a new cationic analog of enterobactin
13. 3+ values
14. Model compounds for microbial iron-transport compounds. Part 1. Solution chemistry and Mössbauer study of iron(II) and iron(IH). Complexes from phenolic and catecholic system
15. Clinically useful chelators of tripositive elements
16. The biochemistry of desferrioxamine and its relation to iron metabolism
17. Orally active hydroxamic acid inhibitors of leukotriene biosynthesis
18. The development of new iron-chelating drugs
19. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload
20. Crystal structure of the tris 1,2-dimethyl-3-hydroxy-4-pyridinone (DMHP) complex with the Fe(III) ion
21. Iron chelation using subcutaneous infusion of diethyl triaminopentaacetic acid (DTPA)
22. Structure, properties, and transport mechanism of iron(HI) complex of mugineic acid, a possible phytosiderophore
23. Hydroxylated phytosiderophore species possess an enhanced chelate stability and affinity for iron(III)
24. 3+
25. Iron and citric acid: A fuzzy chemistry of ubiquitous biological relevance
26. The hydrolytic polymerisation of ferric citrate II. The influence of excess citrate
27. Structural studies of transition metal complexes of triionized and tetraionized citrate. Models or the coordination of the citrate ion to transition metal ions in solutions and at the active site of aconitase
28. Isolation and characterization of staphyloferrin A: A compound with siderophore activity from Staphylococcus hyicus DSM-20459
29. Rhizoferrin-a complexone type siderophore of the Mucorales and Entomophthorales (Zygomycetes)
30. Iron Chelators for clinical use
31. Importance of probe molecular geometry in determining intestinal permeability
32. Jejunal permeability in humans in vivo and rats in situ: Investigation of molecular size selectivity and solvent drag
33. Intestinal permeability: Functional assessment and significance
34. 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 500 as probe markers for assessment in vivo of human intestinal permeability
35. Absorption of polyethylene glycol oligomers (330-1122 Da) is greater in the jejunum than in the ileum of rats
36. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators
37. The development of iron chelating drugs
38. The biochemistry of desferrioxamine and its relation to iron metabolism
39. An improved animal model for studying desferrioxamine
40. Ferrioxamine and its hexadentate iron-chelating metabolites in human postdesferal urine studied by high-performance liquid-chromatography and fast atom bombardment mass-spectrometry
41. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible radioactive detection
42. Intravenous-infusion pharmacokinetics of desferrioxamine in thalassemic patients
43. Intensive iron-chelation therapy with desferrioxamine in ironloading anaemias
44. Transition-metals in control of gene-expression
45. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase
46. Stereochemistry of ethylene diaminetetroaceto complexes
47. Therapeutic iron chelators and their potential side-effects
48. The production of hydroxyl radicals by deferiprone-iron compounds under physiological conditions
49. The search for new-generation olefin polymerization catalysts: Life beyond metallocenes
50. Potential protection from toxicity by oral iron chelators
51. Iron chelating agents with clinical potential
52. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators
53. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: Structure-activity investigation of metalloenzyme inhibition by iron chelators
54. Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase
55. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase
56. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability
57. Lipid solubility and drug penetration of the blood brain barrier
58. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability
59. Mechanism of iron chelation in the hypertransfused rat: Definition of two alternative pathways of iron mobilization
60. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
61. Desferrioxamine toxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
62. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions
63. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions
64. Growth failure and bony changes induced by deferoxamine
65. Industrial aspects of iron chelators: Pharmaceutical application
66. Synthesis and biological evaluation of hydroxamate-based iron chelators
67. Structural alterations in desferrioxamine compatible with iron clearance in animals
68. Subcutaneous depot desferrioxamine (CGH 749B): Relationship of pharmacokinetics to efficacy and drug metabolism
69. Phase I, single dose trial on depot desferrioxamine (CGH 749B) in transfusion-dependent beta-thalassemic patients
70. Iron balance and chelation efficiency following single dose depot desferrioxamine
71. A depot formulation of desferrioxamine (ICL749b): Update on the dose-finding program
72. DTPA in the management of iron overload in thalassaemia
73. Effect of desferrioxamine and DTPA in iron overload
74. New multidentate ligands. IV. Chelating tendencies of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid
75. Synthesis of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′diacetic (HBED) derivatives
76. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N′-bis[2-hydroxybenzyl]-ethylenediamine-N,N′-diacetic acid (HBED)-Comparison with desferrioxamine
77. HBED: A potential alternative to deferoxamine for iron-chelating therapy
78. A comparative evaluation of iron chelators in a primate model
79. Results from phase I clinical trial of HBED
80. Esters and lactones of phenolic amino carboxylic acids: Prodrugs for iron chelation
81. Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: Correlation with physicochemical properties and oral activity
82. Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network
83. Competition between iron(III)-selective chelators and zinc-finger domains for zinc(II)
84. Feasibility of enterochelin as an iron-chelating drug: Studies with human serum and a mouse model system
85. Specific sequestering agents for the actinides. 26. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands
86. Novel 3-hydroxyl-2(1H)-pyridinones. Synthesis, iron(III) chelating properties and biological activity
87. Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxy-l-methyl-2(1H)-pyridinone ligands for in vivo plutonium(IV) chelation
88. High-yield synthesis of the enterobactin trilactone and evaluation of derivative siderophore analogs
89. Synthesis, physico-chemical and iron(III)-chelating properties of novel hexadentate 3-hydroxy-2(1H)pyridinone ligands
90. New multidentate chelators for iron
91. Coordination chemistry of microbial iron transport. 42. Structural and spectroscopic characterisation of diastereometric Cr(III) and Co(III) complexes of desferrithiocin
92. Metal complex formation of a new siderphore desferrithiocin and of three related ligands
93. Desferrithiocin
94. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators
95. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic
96. A new, potent, orally active iron chelator
97. 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid: A novel efficient and selective iron(III) complexing agent
98. Synthesis and investigation of complex compounds of transition metals with di(o-hydroxyphenyl)-1,2,4-oxadiazole and its 1,2,4-triazole analogs
99. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal
100. Mobilization of iron from reticulocytes
101. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs
102. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone
103. Partition-coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy
104. Chelation and mobilization of cellular iron by different classes of chelators
105. Pyridoxal isonicotinoyl hydrazone-an effective iron-chelator after oral-administration
106. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
107. Pyridoxal isonicotinoyl hydrazone (PIH): A promising new iron chelator
108. The synthesis, crystal and molecular-structure, and oxidation-state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulfate
109. Deferiprone-a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases
110. Development of iron-chelating agents for clinical use
111. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
112. Urinary metabolic profiles in man and rat of 1,2-dimethyl- and 1,2-diethyl substituted 3-hydroxypyridin-4-ones
113. An orally active iron chelator
114. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
115. Iron-chelation therapy with oral deferiprone-toxicity or lack of efficacy?
116. Iron chelation with oral deferiprone in patients with thalassemia
117. Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study
118. Deferiprone and neutropenia: Incidence and characteristics in a long-term safety study
119. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice
120. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one CP94, relates to differing metabolism of the iron chelating site
121. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds
122. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine
123. Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat
124. Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolis
125. Metabolism and pharmacokinetics of 1-(2′-hydroxyethyl)- and 1-(3′-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat
126. Novel orally active iron chelators (3 - Hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats
127. Synthesis, physicochemical properties and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones
128. 59Fe-ferritin loaded rat model
129. Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: Design of orally active chelators with clinical potential
130. Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally active iron chelators with clinical potential
131. Design, synthesis, and biological evaluation of aromatic ester prodrugs of 1-(3′-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as orally active iron chelators
132. Metabolism and pharmacokinetics of 1-(2′-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat
133. Hydrolytic and metabolic characteristics of the esters of 1-(3′-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41), potentially useful iron chelators
134. In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: Correlation with physico-chemical properties and oral activity
135. 3+ values
136. 3+ values
137. A risk benefit assessment of iron-chelation therapy
138. New considerations in the treatment of sickle cell disease
139. Transfusion practice for patients with sickle cell disease
140. Iron absorption and loading in β-thalassaemia intermedia
141. Iron chelating-agents with clinical potential
142. Increased nigral iron content in postmortem Parkinsonian brain
143. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents
144. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon
145. Cell-cycle synchronization and growth-inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia-cell lines
146. Iron chelation with desferrioxamine-B in adults with asymptomatic Plasmodium-falciparum parasitemia
147. The antimalaria effect of iron chelators-studies in animal-models and in humans with mild falciparum-malaria
148. The treatment of malaria with iron chelators